Community-acquired Pneumonia
Conditions
Brief summary
Through a series of retrospective analysis, it is hoped that an objective evaluation of the effect and safety of Eucalyptol, Limonene and Pinene Enteric Soft Capsules in the treatment of community-acquired pneumonia can be made.
Interventions
DRUGEucalyptol, Limonene and Pinene Enteric Soft Capsule
Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP\_ONLY and EXP\_ONLY cohort
DRUGAmbroxol injection
Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP+AMB and cohort EXP+AMB Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP+AMB and AMB\_ONLY cohort Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP+AMB and AMB\_ONLY cohort
DRUGOther oral mucolytic drugs
Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP\_ONLY and EXP\_ONLY cohort
Sponsors
Beijing Grand Johamu Pharmaceutical Company, Ltd.
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
1. Patients with community-acquired pneumonia 2. Inpatients from 2017 to 2019 3. Regardless of age and gender
Exclusion criteria
1. Patients diagnosed with hospital-acquired pneumonia 2. Patients who take two or more oral mucolytics 3. Patients with combined use of Chinese and Western expectorants other than mucolytic drugs
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of cough-related symptoms improvement | 7 days | Rate of cough-related symptoms improvement in the expectorant treatment of inpatients with community-acquired pneumonia. Compared the differences of the rates of cough improvement between the experiment group and the control group. The cough-related symptoms are evaluated and recorded in the inpatients' medical records. All the descriptions of cough-related symptoms and assessments in every inpatient's medical records will be captured. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Hospitalization length of stay | Up to 30 days | The mean hospitalization length of stay in every group is analyzed according the discharge summaries. |
| Rate of pulmonary imageological improvement | Up to 30 days | The pulmonary imageological resultes include improved, deteriorative and unchanged states. The improvement rate calculation in every group is based on the improved state according to the last imageological reports before discharge. |
| Rate of normalization of vital signs | 7 days | The vital signs, include temperature, pulse and respirations, are measured during the pre and post treatment. The normalization rate of vital signs is analyzed among the patients with abnormal vital signs measurements before treatment. |
| Rate of overal cure and improvement in pneumonia treatment | Up to 30 days | The overal pneumonia treatment results, include cured, improved, dead and other states, are assessed and recorded in the discharge summaries. The overal cure and improvement rate calculation in every group is based on the cured and improved states. |
| Safety assessment: adverse events | Up to 30 days after first dose | Assess safety through monitoring of adverse events, and the collection of conventional laboratory data. All the adverse events during the pre and post treatment will be captured. |
| Cost-effectiveness ratio | Up to 30 days | The all-cause healthcare will be determined by all the costs happened during the whole hospital stays (i.e.,skilled nursing facility, total medical, prescriptions). Effectiveness will be measured by the primary outcome, the rate of cough-related symptoms improvement within 7 days. The cost-effectiveness ratio is determined by the ratio of the all-cause healthcare to the rate of cough-related symptoms improvement within 7 days. |
| Rate of normalization of inflammatory index of pneumonia | 7 days | The Inflammatory indexes of pneumonia, include CRP, PCT, SAA, WBC, IL-6 and lymphocyte count, are measured during the pre and post treatment. The normalization rates of inflammatory indexes of pneumonia are analyzed among the patients with abnormal indexes measurements before treatment |
Countries
China
Outcome results
None listed